Treatment of Secondary Polycythemia with History of Kidney Transplantation — Post-Transplant Erythrocytosis
Clinical scenario: Haematocrit exceeding 0.51, persisting for more than one month after renal transplantation, with no other identified cause — a commonly used definition of post-transplant erythrocytosis.
Post-transplant erythrocytosis following renal transplantation is a benign, often self-limiting condition which typically develops within the first year following transplantation, although it can occur at 2–4 years. When haematocrit remains persistently elevated beyond one month and is otherwise unexplained, prompt evaluation and treatment are warranted.
Management approach
Management focuses on promptly addressing both hypertension and the persistently elevated haematocrit. The cornerstone involves a specific class of agents targeting the renin-angiotensin system, which has been shown to reduce haematocrit in the majority of patients.
Full agent selection, sequencing, and management algorithm available in the complete protocol →
Clinical goal
The treatment target is reduction of haematocrit, with a nadir level expected at 3 months and stable results maintained over subsequent years.
References
DOI: 10.1111/bjh.15647
A Hct over 0.51 lasting more than a month after renal transplantation is a commonly used definition.
Post-transplant erythrocytosis following renal transplantation is a benign, often self-limiting condition which typically develops within the first year following transplantation, although it can occur at 2–4 years.
Treat hypertension and rising Hct promptly if persistent (>1 month) and otherwise unexplained.
Use angiotensin-converting enzyme inhibitors (e.g. captopril, enalapril) or angiotensin receptor blockers (e.g. losartan).
Treatment with ACEi or angiotensin receptor blockers (ARB) successfully reduces the Hct in the majority.
Treatment with ACEi or ARB reduces Hct to a nadir level at 3 months with stable results for several years.
View source ↗